ReviewMolecular therapy : the journal of the American Society of Gene Therapy2011
New generation of plasmid backbones devoid of antibiotic resistance marker for gene therapy trials.
Review in Molecular therapy : the journal of the American Society of Gene Therapy, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 60 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
60 citing papers in PubMed, 111 citations in OpenAlex.
- Resilience of recombinant antibiotic resistance gene-containing plasmids against common cell culture disposal methods.Cell reports methods · 2026Article
- Development of bicistronic plasmids and fusion proteins for clinical translation of tumor immune reprogramming.Molecular therapy. Advances · 2026Article
- Multi-gene Co-expression systems inSynthetic and systems biotechnology · 2026Review
- Non-viral gene therapy for hemophilia A: long-term outcomes of minicircle FVIII delivery in a mouse model.Frontiers in pharmacology · 2026Article
- Article
- AAVone: A cost-effective, single-plasmid solution for efficient AAV production with reduced DNA impurities.Molecular therapy. Nucleic acids · 2025Article
- A novel miniaturized filamentous phagemid as a gene delivery vehicle to target mammalian cells.Molecular therapy. Nucleic acids · 2025Article
- Article
- Construction of pVAX-1-based linear covalently closed vector with improved transgene expression.Molecular biology reports · 2024Article
- Microbial conversion of ethanol to high-value products: progress and challenges.Biotechnology for biofuels and bioproducts · 2024Review
- Delivery of DNA-Based Therapeutics for Treatment of Chronic Diseases.Pharmaceutics · 2024Review
- Live attenuated-nonpathogenicFrontiers in microbiology · 2024Review
- Engineering E. coli strains using antibiotic-resistance-gene-free plasmids.Cell reports methods · 2023Article
- Salmonella Typhimurium expressing chromosomally integrated Schistosoma mansoni Cathepsin B protects against schistosomiasis in mice.NPJ vaccines · 2023Article
- CRISPRi-based programmable logic inverter cascade for antibiotic-free selection and maintenance of multiple plasmids.Nucleic acids research · 2022Article
- RecombinantAntibiotics (Basel, Switzerland) · 2022Review
- Circuit-guided population acclimation of a synthetic microbial consortium for improved biochemical production.Nature communications · 2022Article
- Article
- Pharmacological hypothesis: A recombinant probiotic for taming bacterial β-glucuronidase in drug-induced enteropathy.Pharmacology research & perspectives · 2022Article
- Hypersecretion of OmlA antigen in Corynebacterium glutamicum through high-throughput based development process.Applied microbiology and biotechnology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Since it has been established that the injection of plasmid DNA can lead to an efficient expression of a specific protein in vivo, nonviral gene therapy approaches have been considerably improved, allowing clinical trials. However, the use of antibiotic resistance genes as selection markers for plasmid production raises safety concerns which are often pointed out by the regulatory authorities. Indeed, a horizontal gene transfer to patient's bacteria cannot be excluded, and residual antibiotic in the final product could provoke allergic reactions in sensitive individuals. A new generation of plasmid backbones devoid of antibiotic resistance marker has emerged to increase the safety profile of nonviral gene therapy trials. This article reviews the existing strategies for plasmid maintenance and, in particular, those that do not require the use of antibiotic resistance genes. They are based either on the complementation of auxotrophic strain, toxin-antitoxin systems, operator-repressor titration, RNA markers, or on the overexpression of a growth essential gene. Minicircles that allow removing of the antibiotic resistance gene from the initial vector will also be discussed. Furthermore, reported use of antibiotic-free plasmids in preclinical or clinical studies will be listed to provide a comprehensive view of these innovative technologies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.